213.45

1.05% -2.27

Pre-market: 214.50 1.05 +0.49%

Quest Diagnostics Inc (DGX)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split Dividend History

Quest Diagnostics Inc stock is traded at $213.45, with a volume of 742.21K. It is down -1.05% in the last 24 hours and up +6.57% over the past month. Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.

Previous Close:

$215.72

Open:

$215.64

24h Volume:

742.21K

Relative Volume:

0.82

Market Cap:

$23.63B

Revenue:

$11.28B

Net Income/Loss:

$1.07B

P/E Ratio:

23.54

EPS:

9.0657

Net Cash Flow:

$1.33B

1W Performance:

+0.38%

1M Performance:

+6.57%

6M Performance:

+18.28%

1Y Performance:

+20.65%

1-Day Range:

$212.57

$216.52

1-Week Range:

$210.67

$217.41

52-Week Range:

$164.65

$217.41

Quest Diagnostics Inc Stock (DGX) Company Profile

Name

Quest Diagnostics Inc

Sector

Healthcare (1100)

Industry

Diagnostics & Research (48)

Phone

(973) 520-2700

Address

500 PLAZA DRIVE, SECAUCUS

Employee

57,000

Twitter

@QuestDX

Next Earnings Date

2026-07-23

Latest SEC Filings

DGX's Discussions on Twitter

Compare DGX vs TMO, DHR, IDXX, NTRA, WAT

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
DGX Quest Diagnostics Inc	213.45	23.46B	11.28B	1.07B	1.33B	9.0657
TMO Thermo Fisher Scientific Inc	517.60	186.32B	45.20B	6.87B	6.75B	18.19
DHR Danaher Corp	193.62	134.82B	24.78B	3.68B	5.29B	5.1743
IDXX Idexx Laboratories Inc	564.98	41.53B	4.45B	1.10B	1.06B	13.59
NTRA Natera Inc	283.80	38.88B	2.50B	-226.32M	71.51M	-1.6412
WAT Waters Corp	378.89	36.82B	3.77B	449.25M	240.68M	7.8556

Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-30-26	Upgrade	Barclays	Equal Weight → Overweight
Aug-25-25	Downgrade	Robert W. Baird	Outperform → Neutral
Apr-02-25	Initiated	Redburn Atlantic	Buy
Mar-04-25	Downgrade	Citigroup	Buy → Neutral
Jan-06-25	Upgrade	Leerink Partners	Market Perform → Outperform
Dec-17-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Dec-10-24	Resumed	Jefferies	Buy
Oct-23-24	Upgrade	Robert W. Baird	Neutral → Outperform
Aug-28-24	Resumed	Evercore ISI	In-line
Jul-10-24	Upgrade	Citigroup	Neutral → Buy
Feb-26-24	Initiated	Leerink Partners	Market Perform
Feb-07-24	Upgrade	Jefferies	Hold → Buy
Jan-03-24	Initiated	Barclays	Equal Weight
Dec-12-23	Upgrade	BofA Securities	Neutral → Buy
Jun-29-23	Initiated	Piper Sandler	Neutral
May-02-23	Downgrade	BofA Securities	Buy → Neutral
Apr-03-23	Upgrade	Citigroup	Sell → Neutral
Jan-23-23	Initiated	Evercore ISI	In-line
Nov-17-22	Downgrade	Citigroup	Neutral → Sell
Aug-22-22	Resumed	Morgan Stanley	Equal-Weight
Apr-04-22	Downgrade	Citigroup	Buy → Neutral
Feb-23-22	Downgrade	UBS	Buy → Neutral
Feb-02-22	Downgrade	Jefferies	Buy → Hold
Jan-28-22	Downgrade	Deutsche Bank	Buy → Hold
May-04-21	Upgrade	UBS	Neutral → Buy
Mar-12-21	Downgrade	Robert W. Baird	Outperform → Neutral
Oct-21-20	Upgrade	Argus	Hold → Buy
Jul-29-20	Upgrade	KeyBanc Capital Markets	Sector Weight → Overweight
Jul-14-20	Upgrade	BofA Securities	Neutral → Buy
Jun-09-20	Upgrade	Wells Fargo	Underweight → Equal Weight
Jun-02-20	Upgrade	Deutsche Bank	Hold → Buy
Apr-28-20	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Apr-27-20	Upgrade	Citigroup	Neutral → Buy
Apr-27-20	Upgrade	Wolfe Research	Underperform → Peer Perform
Mar-27-20	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jan-08-20	Initiated	Wells Fargo	Underweight
Jan-07-20	Downgrade	Barclays	Overweight → Equal Weight
Dec-19-19	Upgrade	BofA/Merrill	Underperform → Neutral
Jul-15-19	Downgrade	Goldman	Neutral → Sell
Apr-02-19	Upgrade	Jefferies	Hold → Buy
Mar-18-19	Resumed	Credit Suisse	Neutral
Jan-31-19	Downgrade	Argus	Buy → Hold
Jan-17-19	Initiated	UBS	Neutral
Jan-03-19	Downgrade	BofA/Merrill	Neutral → Underperform
Dec-03-18	Downgrade	BofA/Merrill	Buy → Neutral
Nov-30-18	Downgrade	Goldman	Buy → Neutral

View All

Quest Diagnostics Inc Stock (DGX) Latest News

Jul 01, 2026

Fund Update: 111,974 QUEST DIAGNOSTICS (DGX) shares added to EASTERN BANK portfolio - Quiver Quantitative

Jul 01, 2026

Quest Diagnostics's Q2 2026 Earnings: What to Expect - Barchart.com

Jul 01, 2026

Jun 29, 2026

Quest Diagnostics Inc. stock outperforms competitors on strong trading day - MarketWatch

Jun 29, 2026

Quest Diagnostics earnings calendar in focus, shares trade steadily on the NYSE - AD HOC NEWS

Jun 29, 2026

Jun 27, 2026

Price to earnings forward of Quest Diagnostics Incorporated – NYSE:DGX - TradingView

Jun 27, 2026

Quest Diagnostics highlights long-term strategy, shares hold near recent highs - AD HOC NEWS

Jun 27, 2026

ETFs Investing in Quest Diagnostics Incorporated Stocks - TradingView

Jun 27, 2026

Jun 26, 2026

Quest Diagnostics Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch

Jun 26, 2026

Jun 25, 2026

Quest Diagnostics Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch

Jun 25, 2026

Quest Diagnostics Incorporated Actuals & Estimates (NYSE:DGX) - TradingView

Jun 25, 2026

Days After Launch, Attunio Health Expands Precision Psychiatry Infrastructure with Quest Diagnostics and Getlabs - Morningstar

Jun 25, 2026

DGX Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026

Jun 24, 2026